This strategy has been shown to be effective in a large number of tumours, as evidenced by the success of CTLA-4 (cytotoxic T-lymphocyte antigen 4) and PD-1 (programmed cell death protein 1) pathway-blocking antibodies [85]. This evidence concerns the gene PDCD1 and neoplasm.